Experimental HIV vaccine induces bnAb production in models
Researchers have developed a vaccine for HIV that has shown success in rabbits, by neutralising a wide range of HIV strains using bnAbs.
List view / Grid view
Researchers have developed a vaccine for HIV that has shown success in rabbits, by neutralising a wide range of HIV strains using bnAbs.
A new discovery on how the immune system responds to malaria infection could lead to better treatments for hepatitis C, HIV and lupus.
A study has revealed a new antibody that reverses the effects of pulmonary arterial hypertension in rodents and cell models.
A new rabies vaccine strategy enhanced the speed and magnitude of the anti-rabies antibody responses and could improve the efficacy of currently used vaccines.
A new vaccine against the Staphylococcus aureus infection has proven effective in experiments with mice, with an 80 percent survival rate.
A study has demonstrated a novel vaccine design in mice which could be used to immunise patients against HIV.
Researchers have identified a set of three antibodies that they suggest could become the basis for a new antiviral treatment and inform the development of new influenza vaccines.
A new study has shown the specific cellular mechanisms that limit the ability of CD8 T cells to infiltrate the tumour microenvironment, which could guide new immunotherapeutic strategies in cancer.
Researchers have identified a protein on the surface of cells that cause MS and have used antibodies as an effective treatment for the condition in mice.
Researchers have shown that a monoclonal antibody prevents viruses from fusing with cell membranes to gain entry.
A new study shows that using therapeutic antibodies to block the interleukin-11 protein can reverse idiopathic pulmonary fibrosis.
Almost all animal subjects exposed to genital herpes were protected by the novel vaccine.
Monoclonal antibodies have shown great promise in the treatment of various cancers. This article discusses how therapeutic antibodies are produced and the various treatment strategies that are currently being adopted.
Marc Baiget-Francesch highlights interesting developments in the field of protein drug design and explains how continual software improvements are speeding up the process.
An experiment with mice has successively blocked the immune system's T cells from killing transplanted cells.